Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study-Reference-Cited by-同舟云学术

Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study

Published:2008-05-20 Issue:12 Volume:134 Page:1385-1396
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Arai Yoichi,Akaza Hideyuki,Deguchi Takashi,Fujisawa Masato,Hayashi Mikio,Hirao Yoshihiko,Kanetake Hiroshi,Naito Seiji,Namiki Mikio,Tachibana Masaaki,Usami Michiyuki,Ohashi Yasuo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-008-0409-z.pdf

Reference21 articles.

1. Akaza H (1999) Prostate cancer therapy and anti-androgens: recent trends. Jpn J Urol Surg 12:623–624

2. Akaza H, Yamaguchi A, Matsuda T et al (2004) Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 34:20–28

3. Akaza H, Yoshida H, Takimoto Y et al (2005) Bicalutamide 80 mg in combination with an LHRHa versus LHRHa monotherapy in previously untreated advanced prostate cancer: a double-blind, placebo controlled trial. J Clin Oncol 23:16S

4. Clark JA, Bokhour BG, Inui TS, Silliman RA, Talcott JA (2003) Measuring patients’ perceptions of the outcomes of treatment for early prostate cancer. Med Care 41:923–936

5. Da Silva FC, Reis E, Costa T, Denis L (1993) Quality of life in patients with prostatic cancer. A feasibility study. The Members of Quality of Life Committee of the EORTC Genitourinary Group. Cancer 71:1138–1142

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study;International Journal of Clinical Oncology;2022-08-10

2. Combined androgen blockade (CAB) versus luteinizing hormone-releasing hormone (LHRH) agonist monotherapy for androgen deprivation therapy;World Journal of Urology;2019-06-11

3. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study;Japanese Journal of Clinical Oncology;2018-10-26

4. Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade;Prostate International;2018-03

5. Predictors of health-related quality of life in Korean prostate cancer patients receiving androgen deprivation therapy;European Journal of Oncology Nursing;2017-10